TP53 and thyroid cancer: In addition, in vitro studies revealed that PRIMA-1 decreases the viability of thyroid cancer cells harboring p53 mutations and enhances the cytotoxic effects of doxorubicin and cisplatin in chemotherapy-resistant thyroid cancer cells [182].